<DOC>
	<DOC>NCT00737776</DOC>
	<brief_summary>This study is conducted in Asia. The aim of this observational study is to evaluate the efficacy on blood glucose control while using NovoMix® 30 FlexPen® under normal clinical practice conditions in Korea. A clinical safety profile will be also evaluated.</brief_summary>
	<brief_title>Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Any patient with type 1 and type 2 diabetes who are treated with NovoMix® 30 Patient who signed on informed consent form Patients who are unlikely to comply with protocol requirements, e.g., uncooperative attitude, inability to return for the final visit Patients who were previously enrolled in this study Patients with a hypersensitivity to NovoMix® 30 or to any of the excipients Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 12 months</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>